HC Wainwright Predicts BioNTech's Q4 Earnings (NASDAQ:BNTX)

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - HC Wainwright lowered their Q4 2025 EPS estimates for BioNTech in a report issued on Monday, June 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of $0.51 per share for the quarter, down from their previous forecast of $0.52. HC Wainwright currently has a "Buy" rating and a $138.00 price target on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($0.72) EPS and FY2026 earnings at ($5.35) EPS.

BNTX has been the topic of several other research reports. Citigroup reiterated a "buy" rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Truist Financial reiterated a "buy" rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Finally, Morgan Stanley reduced their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and a consensus target price of $137.86.

BioNTech Trading Up 2.0%

NASDAQ BNTX traded up $2.13 during trading on Wednesday, hitting $106.53. The company had a trading volume of 721,507 shares, compared to its average volume of 950,228. The company's fifty day moving average is $102.22 and its 200-day moving average is $107.64. The company has a market cap of $25.61 billion, a price-to-earnings ratio of -31.33 and a beta of 1.29. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. BioNTech has a one year low of $76.53 and a one year high of $131.49.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of BioNTech by 22.2% in the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after buying an additional 1,401,547 shares in the last quarter. Flossbach Von Storch SE lifted its position in BioNTech by 1.1% during the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock valued at $502,160,000 after purchasing an additional 47,236 shares during the period. Capital International Investors lifted its position in BioNTech by 38.6% during the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after purchasing an additional 394,434 shares during the period. BNP Paribas Financial Markets lifted its position in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock valued at $108,859,000 after purchasing an additional 581,173 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in BioNTech by 18,892.9% during the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after purchasing an additional 694,691 shares during the period. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.